A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children

PHASE2CompletedINTERVENTIONAL
Enrollment

636

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Dengue FeverDengue Hemorrhagic FeverDengue Shock Syndrome
Interventions
OTHER

Placebo

"Lyophilized, single dose vials and sterile water for~\> injection; 0.5 mL dose; Vaccination schedule: 0, 6 months"

BIOLOGICAL

T-DEN-Post-Transfection F17

Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months

BIOLOGICAL

T-DEN-Post-Transfection F19

Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months

Trial Locations (11)

00725

San Juan Batista Medical School, Caguas

00983

Private Practice, Carolina

00733

St Luke's Memorial Hospital, Ponce

00926

Private Practice, Rio Piedras

00935

RCMI Clinical Research Center, Rio Piedras

00745

Caparra Internal Medicine Research Center, Río Grande

00683

Torre Medica San Vicente de Paul, San Germán

00909-1711

Clinical Research PR, San Juan

00917

Centro de Neumologia Pediatricia, San Juan

00921

Private Practice, San Juan

00936-5067

Dept Pediatria, Esc. De Medicina, San Juan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

U.S. Army Medical Research and Development Command

FED